Last updated: September 23, 2026
Lopurin is an allopurinol prescription product used to reduce uric acid in gout, hyperuricemia associated with cancer therapy, and selected uric-acid disorders. Its commercial profile is that of a mature generic-market product rather than a protected branded medicine. Market growth is driven by gout prevalence, treatment persistence, and generic supply conditions, while revenue is constrained by low unit prices, multiple manufacturers, and substitution with other allopurinol products.
Standalone Lopurin sales are not publicly reported. Its financial trajectory is therefore best assessed through allopurinol market volume, U.S. prescription dynamics, generic pricing, manufacturer participation, and competition from febuxostat and other urate-lowering therapies.
What is Lopurin and how is it positioned in the pharmaceutical market?
Lopurin is an oral allopurinol product available primarily in 100 mg and 300 mg tablet strengths. Allopurin inhibits xanthine oxidase, reducing production of uric acid. It is used for chronic gout management and for hyperuricemia related to chemotherapy or other high-cell-turnover conditions. The product is not an innovative active pharmaceutical ingredient and does not have the commercial characteristics of a patent-protected specialty drug.
| Attribute |
Lopurin market profile |
| Active ingredient |
Allopurinol |
| Drug class |
Xanthine oxidase inhibitor |
| Principal dosage form |
Immediate-release oral tablet |
| Common strengths |
100 mg and 300 mg |
| Primary uses |
Gout, hyperuricemia, tumor lysis-related uric acid elevation |
| FDA pathway |
Generic prescription product |
| Typical market structure |
Multi-source generic |
| Biosimilar exposure |
None |
| Current commercial thesis |
Stable demand, low price, limited brand differentiation |
Allopurinol remains a first-line urate-lowering therapy under American College of Rheumatology guidance, including for many patients with moderate-to-severe chronic kidney disease. The guideline recommends low starting doses followed by dose titration, which supports recurring prescription demand but limits premium pricing. [1]
How large is the Lopurin and allopurinol market?
The relevant market is the U.S. allopurinol market, not Lopurin as an isolated brand. Pharmacies and payers frequently substitute among therapeutically equivalent allopurinol products. Product-level volume can therefore move between manufacturers without changing overall treatment demand.
Demand is supported by:
- Persistent gout prevalence in the U.S.
- Longer patient survival with chronic kidney disease and cardiometabolic disease.
- Greater emphasis on achieving serum urate targets.
- Continued use of allopurinol in oncology-related hyperuricemia.
- Low acquisition cost compared with febuxostat and biologic or specialty therapies.
Demand is limited by:
- Treatment discontinuation caused by adherence problems.
- Titration delays and adverse-reaction concerns.
- Competition from other generic allopurinol suppliers.
- Use of febuxostat in patients who cannot tolerate or do not respond adequately to allopurinol.
- Patient switching between manufacturers based on pharmacy inventory and payer contracts.
U.S. gout prevalence has been estimated at roughly 4% of adults, with higher rates among older adults and patients with kidney, cardiovascular, metabolic, and hypertensive conditions. [2] These epidemiological factors create a large recurring-treatment base, but they do not translate into high revenue per prescription because allopurinol is an established generic medicine.
What is the financial trajectory for Lopurin?
Lopurin’s standalone revenue is not disclosed in public filings. The product is not generally reported as a separate revenue segment by its manufacturer, and available public information does not establish a reliable Lopurin-specific sales figure, gross margin, or prescription count.
The financial trajectory is therefore characterized by the following pattern:
| Period |
Expected commercial condition |
Financial implication |
| Early generic-market phase |
Multiple entrants and rapid price compression |
Declining unit revenue |
| Mature generic phase |
Stable prescription volume and low prices |
Low but recurring cash flow |
| Supply-constrained periods |
Temporary allocation or wholesaler shortages |
Potential price and share volatility |
| Long-term outlook |
Continued clinical use with limited innovation |
Volume stability, weak pricing power |
Revenue growth is unlikely to come from price increases. It would more likely result from:
- Increased allopurinol treatment rates.
- A manufacturer gaining formulary or wholesaler share.
- Supply disruptions affecting competitors.
- Additional institutional or oncology demand.
- Geographic expansion into markets where allopurinol remains underused.
For an owner or distributor, the principal economic value is operational rather than intellectual-property based. Manufacturing cost, supply reliability, contract access, and channel reach are more important than brand recognition.
When does Lopurin lose exclusivity, and what patents protect it?
Lopurin has no meaningful remaining composition-of-matter exclusivity. Allopurinol was introduced decades ago, and the active ingredient is available from multiple generic manufacturers.
| IP category |
Lopurin exposure |
| Active-ingredient patent |
Expired |
| Original product patent |
Expired |
| New chemical entity exclusivity |
Expired |
| FDA orphan exclusivity |
No current Lopurin-specific protection identified |
| Immediate-release formulation patent |
No commercially significant protection identified |
| Method-of-use patent |
No relevant blocking protection identified for standard gout use |
| Manufacturing patent |
Potentially relevant to individual suppliers, but not a product-level barrier |
| Biosimilar exclusivity |
Not applicable |
The FDA Orange Book is relevant for identifying patents and exclusivity associated with approved drug products, but a mature generic allopurinol product does not ordinarily carry an Orange Book patent estate comparable to a branded small-molecule product. [3]
Any supplier-specific process patent would generally affect manufacturing freedom to operate rather than prevent competitors from marketing allopurinol made through other processes.
What is the Orange Book status of Lopurin?
Lopurin should be treated as a generic prescription product rather than as a branded reference product with active Orange Book exclusivity. The commercial questions are therefore:
- Whether the product has an active FDA marketing listing.
- Whether the listed manufacturer continues to supply the product.
- Whether the applicable NDCs remain active.
- Whether wholesalers and pharmacies can source the labeled strengths.
- Whether the product is therapeutically substitutable under state pharmacy rules.
Orange Book status does not by itself establish commercial availability. FDA listing, NDC activity, wholesaler inventory, and manufacturer distribution are separate issues. A product may remain an approved generic while experiencing limited commercial distribution.
Which companies compete with Lopurin?
Competition comes from generic allopurinol manufacturers and from non-allopurinol urate-lowering products.
Generic allopurinol competitors
The competitive set can include products marketed by large generic companies, specialty generic suppliers, and contract manufacturers. Supplier participation can change because of discontinuations, facility issues, portfolio rationalization, or low margins.
The main competitive variables are:
- Lowest acquisition cost.
- Guaranteed supply.
- 100 mg and 300 mg availability.
- Packaging suitable for retail and institutional channels.
- Payer and pharmacy network access.
- Ability to maintain FDA-compliant manufacturing.
Because clinical differentiation is minimal, a manufacturer rarely wins through physician preference alone. Pharmacy benefit managers, wholesalers, and retail purchasing groups exert greater influence.
Febuxostat
Febuxostat is the principal branded and generic pharmacologic alternative in the xanthine oxidase inhibitor category. It may be used when allopurinol is ineffective, not tolerated, or clinically unsuitable. Its use is affected by cardiovascular safety considerations and prescribing guidance, which can preserve allopurinol’s first-line position. [1,4]
Pegloticase and other specialty therapies
Pegloticase is reserved for severe, refractory chronic gout and does not directly compete with Lopurin for ordinary maintenance therapy. Its cost, infusion administration, and specialist use place it in a separate commercial segment.
What formulation patents protect Lopurin?
Lopurin is primarily an immediate-release tablet. No product-level formulation barrier is evident for the ordinary 100 mg and 300 mg tablet market.
Potential formulation-related issues include:
- Tablet excipient composition.
- Dissolution characteristics.
- Manufacturing process controls.
- Packaging and stability.
- Scored-tablet design.
- Combination products or modified-release presentations.
These features generally do not create durable exclusivity for standard allopurinol tablets. A supplier may hold confidential manufacturing know-how or process controls, but such know-how is unlikely to prevent multiple generic competitors from supplying equivalent products.
Are there Paragraph IV challenges or patent litigation involving Lopurin?
A conventional Paragraph IV challenge is unlikely to be commercially significant for Lopurin because the relevant allopurinol patents are long expired and the product is not supported by a current branded patent strategy.
No active Lopurin-specific patent dispute is identified in the core FDA product and Orange Book framework. Litigation risk is more likely to arise from:
- Manufacturing compliance actions.
- Product liability claims.
- Labeling disputes.
- Distribution contracts.
- Generic supply agreements.
- Patent disputes involving a new formulation or combination product rather than standard Lopurin tablets.
A Paragraph IV filing would have limited strategic value unless tied to a newly protected formulation, delivery system, or method of use. None is central to the ordinary Lopurin business model.
What FDA regulatory issues affect Lopurin?
The principal regulatory risks are manufacturing and pharmacovigilance issues, not loss of patent exclusivity.
Allopurinol labeling includes important safety information concerning severe cutaneous adverse reactions, hypersensitivity, renal impairment, and dose selection. The FDA-approved labeling recommends lower starting doses in patients with renal impairment and emphasizes discontinuation for serious hypersensitivity reactions. [5]
Genetic risk screening also affects prescribing. The HLA-B*58:01 allele is associated with increased risk of allopurinol hypersensitivity in certain populations. The American College of Rheumatology conditionally recommends testing before treatment in selected higher-risk patient groups, including many patients of Southeast Asian and African American ancestry. [1]
Regulatory exposure includes:
- Failure to maintain current manufacturing compliance.
- Inadequate control of tablet potency or dissolution.
- Labeling errors.
- Inconsistent supply of essential strengths.
- Adverse-event reporting failures.
- Recalls or wholesale product discontinuations.
How strong is the Lopurin patent estate?
The Lopurin patent estate is weak from a market-exclusivity perspective. Its commercial strength depends on supply execution, not patent barriers.
| Strength factor |
Assessment |
| Composition-of-matter protection |
None remaining |
| Formulation exclusivity |
Limited or absent for standard tablets |
| Method-of-use exclusivity |
Limited or absent for standard gout treatment |
| Generic substitution resistance |
Low |
| Manufacturing differentiation |
Possible but supplier-specific |
| Regulatory moat |
Moderate only if supply and compliance are reliable |
| Pricing power |
Low |
| Litigation leverage |
Low |
The product may still generate recurring revenue because clinical demand persists. A weak patent estate does not mean zero commercial value; it means that value is vulnerable to price competition and supply substitution.
What generic launch scenarios exist for Lopurin?
Base case
Allopurin demand remains stable, while Lopurin retains a limited share of a mature multi-source generic market. Revenue remains flat to modestly declining in nominal terms because volume is offset by price erosion.
Upside case
Lopurin gains share through competitor shortages, improved wholesaler access, or a supply contract with a large pharmacy or institutional customer. Revenue increases through volume rather than price.
Downside case
The manufacturer exits the product, loses a major customer, or experiences quality or supply problems. Pharmacies substitute another allopurinol supplier quickly because the product has minimal brand loyalty and no meaningful patent protection.
Strategic upside
The product can support a broader portfolio strategy involving other generic rheumatology, nephrology, or oncology medicines. The value of Lopurin increases when its manufacturing and distribution infrastructure are shared with related products.
How does Lopurin compare with febuxostat?
| Factor |
Lopurin/allopurinol |
Febuxostat |
| Market maturity |
Very mature |
Mature but newer |
| Typical price position |
Low-cost generic |
Higher historically, now generic in many markets |
| Guideline position |
Usual first-line option |
Alternative for selected patients |
| Patent position |
Expired |
Original exclusivity expired in major markets |
| Cardiovascular concern |
Hypersensitivity and dosing risks |
Cardiovascular safety considerations |
| Generic competition |
Extensive |
Increasing |
| Commercial differentiation |
Minimal |
Some clinical differentiation |
| Revenue potential |
Volume-driven |
More dependent on indication and prescribing choice |
Allopurinol’s first-line status and low cost give it a durable volume advantage. Febuxostat can capture patients who do not achieve urate control or cannot tolerate allopurinol, but it is not positioned to eliminate the core allopurinol market.
What geographic markets matter for Lopurin?
The United States is the most relevant market for FDA-regulated Lopurin. Internationally, allopurinol is widely available under numerous local brand and generic names. Geographic expansion is constrained by:
- Local registration requirements.
- Pricing controls.
- Tender-based procurement.
- Local manufacturing rules.
- Pharmacovigilance obligations.
- Competition from domestic generic suppliers.
In lower-price markets, supply reliability and government procurement access can matter more than brand identity. In regulated markets, the manufacturer must maintain country-specific approvals, quality documentation, and pharmacovigilance systems.
Key Takeaways
- Lopurin is an allopurinol generic with recurring clinical demand and limited commercial differentiation.
- Standalone Lopurin revenue is not publicly disclosed.
- The financial trajectory is likely stable to declining on a per-unit basis, with volume dependent on gout prevalence, treatment persistence, and supplier share.
- Allopurinol has no meaningful remaining composition-of-matter exclusivity.
- Standard Lopurin tablets have no evident patent barrier capable of limiting generic substitution.
- Paragraph IV litigation and biosimilar risk are not central to the product.
- The principal risks are price erosion, manufacturer withdrawal, supply disruption, quality compliance, and substitution by other allopurinol suppliers.
- The strongest commercial advantage is low cost combined with first-line guideline positioning.
- Febuxostat is the main pharmacologic competitor, but its safety and cost profile preserve allopurinol’s core market.
- Any investment thesis should focus on manufacturing economics, distribution contracts, supply reliability, and portfolio synergies rather than patent value.
FAQs About Lopurin Market and Commercial Outlook
Is Lopurin still commercially relevant?
Yes. Allopurinol remains a widely used first-line urate-lowering therapy. Lopurin’s relevance comes from the active ingredient’s clinical position, not from brand exclusivity.
Can a generic manufacturer launch a competing allopurinol product?
Yes. Expired patents and the established generic status of allopurinol permit multiple manufacturers to compete, subject to FDA approval and manufacturing compliance.
Does Lopurin have biosimilar competition?
No. Allopurinol is a small-molecule drug, so competing products are regulated as generics rather than biosimilars.
What could increase Lopurin revenue?
The most credible drivers are increased prescription volume, new institutional contracts, competitor supply shortages, improved wholesaler access, and entry into additional regulated markets.
Is Lopurin a strong pharmaceutical acquisition target?
It is unlikely to command a premium based on intellectual property. Its value would depend on reliable supply, manufacturing cost, customer contracts, regulatory history, and fit with a broader generic portfolio.
References
-
FitzGerald, J. D., Dalbeth, N., Mikuls, T., Brignardello-Petersen, R., Guyatt, G., Abhishek, A., et al. (2020). 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care & Research, 72(6), 744-760.
-
Zhu, Y., Pandya, B. J., & Choi, H. K. (2011). Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis & Rheumatism, 63(10), 3136-3141.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2019). Uloric (febuxostat) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2023). Allopurinol tablets prescribing information. FDA.
